These results suggested that BZYQF ameliorated hyposalivation in T2DM individuals mainly via the β1-AR/PKA/AMY1 pathway mediating salivary protein secretion and the CHRM3/IP3R/AQP5 pathway mediating salivary liquid secretion. Here, AQP5 is linked to type 2 diabetes mellitus.